DepressionNCT03129282
Pathway Study WS3 - Home Based Metacognitive Therapy for Cardiac Rehabilitation Patients
A study testing Home-based Metacognitive Therapy (Home-MCT) in people with Depression and Anxiety, run by University of Manchester at 2 sites in United Kingdom.
Trial summary
Depression and anxiety are highly prevalent in people with heart disease, causing immense human and economic burden. Available pharmacological and psychological interventions have limited efficacy and the needs of these patients are not being met in cardiac rehabilitation services despite emphasis in key NHS policy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Depression, Anxiety, Cardiac Rehabilitation
- What is being tested?
- Home-based Metacognitive Therapy (Home-MCT)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 108 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 4 Apr 2017to 14 Mar 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who are referred to the CR pathway who meet Department of Health (DoH) and/or British Association for Cardiovascular Prevention and Rehabilitation (BACPR) CR eligibility criteria:
- Acute coronary syndrome used for any condition brought on by sudden, reduced blood flow to the heart
- Following revascularisation is the restoration of perfusion to a body part or organ that has suffered ischemia
- Stable heart failure
- Stable angina is chest pain or discomfort that most often occurs with activity or stress
- Following implantation of cardioverter defibrillators/cardiac resynchronisation devices
Show all 13Show fewer
- Heart valve repair/replacement
- Heart transplantation and ventricular assist devices
- Adult congenital heart disease identified in adulthood
- Other (atypical heart presentation: nausea, dizziness, lower chest discomfort, upper abdominal pressure or discomfort that feels like indigestion and upper back pain)
- A score of ≥ 8 on either the depression or anxiety subscale of the Hospital Anxiety and Depression Scale
- Minimum of 18 years old
- Competent level of English language skills
Who cannot join
- Cognitive impairment which precludes informed consent or ability to participate
- Acute suicidality
- Active psychotic disorders (i.e., two [or more] of the following: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behaviour, negative symptoms).
- Current drug/alcohol abuse (A maladaptive pattern of drinking, leading to clinically significant impairment or distress)
- Concurrent psychological intervention for emotional distress that is not part of usual care
- Antidepressant or anxiolytic medications initiated in the previous 8 weeks
- Life expectancy of less than 12 months
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Bolton NHS Foundation Trust
Bolton
Aintree Liverpool NHS Foundation Trust
Liverpool
About this study
Official title: A Feasibility Study on Integrating Home-based Metacognitive Therapy for Anxiety and Depression in the Cardiac Rehabilitation Pathway (PATHWAY STUDY WS3)
Depression and anxiety are highly prevalent in people with heart disease, causing immense human and economic burden. Available pharmacological and psychological interventions have limited efficacy and the needs of these patients are not being met in cardiac rehabilitation services despite emphasis in key NHS policy.
Extensive evidence shows that a particular style of thinking dominated by rumination (dwelling on the past) and worry maintains emotional distress. A psychological intervention called metacognitive therapy (MCT) that reduces this style of thinking alleviates depression and anxiety in mental health settings.
This is a single-blind feasibility randomised controlled trial of metacognitive therapy delivered in a home-based format (Home-MCT). The aim of the study is to evaluate the acceptability and feasibility of integrating Home-MCT into cardiac rehabilitation services and to provide provisional evidence of effectiveness and cost-effectiveness on Home-MCT.
- Conditions
- Depression, Anxiety, Cardiac Rehabilitation, Psychological Distress
- Being tested
- Home-based Metacognitive Therapy (Home-MCT)
- Medical subject headings
- Depression, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Home-based Metacognitive Therapy (Home-MCT)Other
Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Participants allocated to the "control" group will receive treatment as usual for cardiac rehabilitation |
| Intervention | Active comparator | Participants allocated to the "intervention" group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT) Receives: Other: Home-based Metacognitive Therapy (Home-MCT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptability
Acceptability of the intervention is defined as the completion of the first 4 modules of the Home-MCT manual, which includes 6 modules in total. Acceptability will be expressed as a % of all patients randomised to the treatment arm, minus deaths. This will be compared to the % of controls (minus deaths) who complete the 4-month follow up.
Measured: From the completion of the manual till 4 months
Secondary outcomes (9)
Change in the Hospital Anxiety and Depression Scale (HADS)
The HADS is a 14-item self-report scale assessing anxiety and depression
Measured: Baseline, 4 months follow up, 12 months follow up
Metacognitions Questionnaire 30 (MCQ-30)
The MCQ-30 is a 30-item self-report scale that measures: a) Lack of Cognitive Confidence, b) Positive Beliefs about Worry, c) Cognitive Self-Consciousness, d) Negative Beliefs about Uncontrollability and Danger, and e) Need to Control Thoughts
Measured: Baseline, 4 months follow up, 12 months follow up
Cognitive Attentional Syndrome Scale (CAS-1)
The CAS-1 is a 10-item self-report measure assessing: a) the degree to which individuals have been dwelling on or worrying and/or focusing attention on threats, b) strategies used to cope with negative feelings and thoughts, and c) the degree to which individuals hold positive and negative metacognitive beliefs about worry
Measured: Baseline, 4 months follow up, 12 months follow up
Impact of Events Scale - Revised (IES-R)
The IES-R is a 22-item self-report measure that assesses subjective distress caused by traumatic events
Measured: Baseline, 4 months follow up, 12 months follow up
Health Related Quality of Life (EQ-5D)
The ED-5D is a standardised questionnaire for use as a measure of health status. It assesses: a) mobility, b) self-care, c) usual activities, d) pain/discomfort, and e) anxiety/depression, and the overall health status
Measured: Baseline, 4 months follow up, 12 months follow up
Economic Patient Questionnaire (EPQ)
The EPQ assesses the services the patients have used as part of their health and social care
Measured: Baseline, 4 months follow up, 12 months follow up
Credibility questionnaire (regarding the Home-MCT intervention)
This is a 3-item self-report questionnaire assessing Home-MCT credibility to reduce psychological distress
Measured: From the completion of the introduction of the Home-MCT manual up to 2 weeks
Adherence questionnaire (regarding the Home-MCT intervention)
This is a 6-item self-report questionnaire assessing adherence to Home-MCT
Measured: From the completion of the manual up to 4 months
Qualitative interviews with intervention patients to identify enablers and barriers to recruitment and engagement with the intervention (Home-MCT)
Interviews are aimed to explore patient's experiences of going through the Home-MCT intervention
Measured: Up to 2 weeks before receiving the intervention and up to 1 month after the completion of the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2017
- Study start4 Apr 2017
- Primary completion20 Jun 2018
- Study completion14 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for DepressionStudies of the same condition, open and under way.
- More trials run by University of ManchesterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 108 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Manchester
- Sponsor type
- University, hospital or other
- Collaborators
- Greater Manchester Mental Health NHS Foundation Trust, University of Liverpool
- Responsible party
- Principal investigator, Adrian Wells, University of Manchester
- Investigators
- Adrian Wells, PhD, Principal investigator, University of Manchester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03129282
- Sponsor's protocol ID
- 186990 (RP-PG-1211-20011)
- Status last verified
- Mar 2023
- First submitted
- 11 Apr 2017
- Last updated
- 22 Mar 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Wells A, Reeves D, Heal C, Fisher P, Doherty P, Davies L, Heagerty A, Capobianco L. Metacognitive therapy self-help for anxiety-depression: Single-blind randomized feasibility trial in cardiovascular disease. Health Psychol. 2022 May;41(5):366-377. doi: 10.1037/hea0001168.
PubMed 35467904Wells A, Reeves D, Heal C, Davies LM, Shields GE, Heagerty A, Fisher P, Doherty P, Capobianco L. Evaluating Metacognitive Therapy to Improve Treatment of Anxiety and Depression in Cardiovascular Disease: The NIHR Funded PATHWAY Research Programme. Front Psychiatry. 2022 Jun 3;13:886407. doi: 10.3389/fpsyt.2022.886407. eCollection 2022.
PubMed 35722590Wells A, McNicol K, Reeves D, Salmon P, Davies L, Heagerty A, Doherty P, McPhillips R, Anderson R, Faija C, Capobianco L, Morley H, Gaffney H, Heal C, Shields G, Fisher P. Metacognitive therapy home-based self-help for cardiac rehabilitation patients experiencing anxiety and depressive symptoms: study protocol for a feasibility randomised controlled trial (PATHWAY Home-MCT). Trials. 2018 Aug 16;19(1):444. doi: 10.1186/s13063-018-2826-x.
PubMed 30115112
Study at a glance
From the registry record, last updated by the sponsor on 22 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Feasibility Study on Integrating Home-based Metacognitive Therapy for Anxiety and Depression in the Cardiac Rehabilitation Pathway (PATHWAY STUDY WS3)
- ClinicalTrials.gov ID
- NCT03129282
- Acronym / sponsor ID
- 186990 (RP-PG-1211-20011)
- Conditions
- Depression, Anxiety, Cardiac Rehabilitation, Psychological Distress
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 108 participants (actual)
- Lead sponsor
- University of ManchesterUniversity, hospital or other
- Collaborators
- Greater Manchester Mental Health NHS Foundation Trust, University of Liverpool
- Study start
- 4 Apr 2017 (actual)
- Primary completion
- 20 Jun 2018 (actual)
- Study completion
- 14 Mar 2019 (actual)
- First posted
- 26 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Depression and anxiety are highly prevalent in people with heart disease, causing immense human and economic burden. Available pharmacological and psychological interventions have limited efficacy and the needs of these patients are not being met in cardiac rehabilitation services despite emphasis in key NHS policy.
Extensive evidence shows that a particular style of thinking dominated by rumination (dwelling on the past) and worry maintains emotional distress. A psychological intervention called metacognitive therapy (MCT) that reduces this style of thinking alleviates depression and anxiety in mental health settings.
This is a single-blind feasibility randomised controlled trial of metacognitive therapy delivered in a home-based format (Home-MCT). The aim of the study is to evaluate the acceptability and feasibility of integrating Home-MCT into cardiac rehabilitation services and to provide provisional evidence of effectiveness and cost-effectiveness on Home-MCT.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Participants allocated to the "control" group will receive treatment as usual for cardiac rehabilitation |
| Intervention | Active comparator | Other: Home-based Metacognitive Therapy (Home-MCT)Participants allocated to the "intervention" group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Patients who are referred to the CR pathway who meet Department of Health (DoH) and/or British Association for Cardiovascular Prevention and Rehabilitation (BACPR) CR eligibility criteria:
- A score of ≥ 8 on either the depression or anxiety subscale of the Hospital Anxiety and Depression Scale
- Minimum of 18 years old
- Competent level of English language skills
Key exclusion criteria (7 listed)
- Cognitive impairment which precludes informed consent or ability to participate
- Acute suicidality
- Active psychotic disorders (i.e., two [or more] of the following: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behaviour, negative symptoms).
- Current drug/alcohol abuse (A maladaptive pattern of drinking, leading to clinically significant impairment or distress)
- Concurrent psychological intervention for emotional distress that is not part of usual care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Home-based Metacognitive Therapy (Home-MCT)Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual. | Other | Intervention |
Primary outcome
Acceptability
Time frame: From the completion of the manual till 4 months
Acceptability of the intervention is defined as the completion of the first 4 modules of the Home-MCT manual, which includes 6 modules in total. Acceptability will be expressed as a % of all patients randomised to the treatment arm, minus deaths. This will be compared to the % of controls (minus deaths) who complete the 4-month follow up.
9 secondary outcomes
Change in the Hospital Anxiety and Depression Scale (HADS)
Time frame: Baseline, 4 months follow up, 12 months follow up
Metacognitions Questionnaire 30 (MCQ-30)
Time frame: Baseline, 4 months follow up, 12 months follow up
Cognitive Attentional Syndrome Scale (CAS-1)
Time frame: Baseline, 4 months follow up, 12 months follow up
Impact of Events Scale - Revised (IES-R)
Time frame: Baseline, 4 months follow up, 12 months follow up
Health Related Quality of Life (EQ-5D)
Time frame: Baseline, 4 months follow up, 12 months follow up
Economic Patient Questionnaire (EPQ)
Time frame: Baseline, 4 months follow up, 12 months follow up
Credibility questionnaire (regarding the Home-MCT intervention)
Time frame: From the completion of the introduction of the Home-MCT manual up to 2 weeks
Adherence questionnaire (regarding the Home-MCT intervention)
Time frame: From the completion of the manual up to 4 months
Qualitative interviews with intervention patients to identify enablers and barriers to recruitment and engagement with the intervention (Home-MCT)
Time frame: Up to 2 weeks before receiving the intervention and up to 1 month after the completion of the intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Mar 2023.
- Results publication: PubMed 35467904Wells A, Reeves D, Heal C, Fisher P, Doherty P, Davies L, Heagerty A, Capobianco L. Metacognitive therapy self-help for anxiety-depression: Single-blind randomized feasibility trial in cardiovascular disease. Health Psychol. 2022 May;41(5):366-377. doi: 10.1037/hea0001168.
- Derived from this study: PubMed 35722590Wells A, Reeves D, Heal C, Davies LM, Shields GE, Heagerty A, Fisher P, Doherty P, Capobianco L. Evaluating Metacognitive Therapy to Improve Treatment of Anxiety and Depression in Cardiovascular Disease: The NIHR Funded PATHWAY Research Programme. Front Psychiatry. 2022 Jun 3;13:886407. doi: 10.3389/fpsyt.2022.886407. eCollection 2022.
- Derived from this study: PubMed 30115112Wells A, McNicol K, Reeves D, Salmon P, Davies L, Heagerty A, Doherty P, McPhillips R, Anderson R, Faija C, Capobianco L, Morley H, Gaffney H, Heal C, Shields G, Fisher P. Metacognitive therapy home-based self-help for cardiac rehabilitation patients experiencing anxiety and depressive symptoms: study protocol for a feasibility randomised controlled trial (PATHWAY Home-MCT). Trials. 2018 Aug 16;19(1):444. doi: 10.1186/s13063-018-2826-x.
- Web-site with details about the studyLink provided by the sponsor.
Related trials for Depression
Recruiting
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
Major Depressive Disorder
Recruiting
Metacognitive Bibliotherapy for Anxiety, Depression, and Metacognitions in University Students
Anxiety, Depression
Enrolling by invitation
Vagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement
Treatment Resistant Depression
Active, not recruiting
NYUCI-ES: Psychosocial Intervention to Improve Health Outcomes for Chinese and Korean ADRD Caregivers
Dementia Caregivers, Diabetes
Enrolling by invitation
Intervention to Reduce HIV Related Stigma Among Pregnant and Postpartum Women
HIV, HIV - Human Immunodeficiency Virus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adrian Wells, PhD principal investigator
University of Manchester
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Home-based Metacognitive Therapy (Home-MCT) in people with Depression and Anxiety, run by University of Manchester at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acceptability (time frame: From the completion of the manual till 4 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03129282, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2023.